News & Media


Larner College of Medicine in the Media

The following news and stories about LCOM appeared in local and/or national media.


Cunniff Presents New Cancer Research at iMig Conference

August 3, 2023 by Lucy Gardner Carson

(AUGUST 3, 2023) At the 2023 International Mesothelioma Interest Group (iMig) conference in June, Brian Cunniff, Ph.D., assistant professor of pathology, presented early experience with “an exciting new therapeutic option for patients suffering with mesothelioma” to a global audience of clinicians, scientists, and allied professionals, according to Business Wire.

Brian Cunniff, Ph.D., assistant professor of pathology and laboratory medicine and chief science officer for RS Oncology

(AUGUST 3, 2023) At the 2023 International Mesothelioma Interest Group (iMig) conference hosted in Lille, France, in June, Brian Cunniff, Ph.D., assistant professor of pathology and laboratory medicine and chief science officer for RS Oncology (RSO), presented early experience with “an exciting new therapeutic option for patients suffering with mesothelioma” to a global audience of clinicians, scientists, and allied professionals, according to Business Wire.

“RSO-021 is an exciting new therapeutic option for patients suffering with mesothelioma,” Cunniff said. “RSO-021 exploits a universal vulnerability of tumor cells through a novel mechanism of action, leaving tumor cells unable to clear toxic waste products. We are excited to see our laboratory findings translated to patients in collaboration with RS Oncology.”

Watch a short clip from the symposium in which Dr. Cunniff explains the discovery of PRX3 and its role in cancer tumors. 

Read full story at Business Wire

Larner College of Medicine News

Recent news and stories from the college.

Cunniff Presents New Cancer Research at iMig Conference

August 3, 2023 by Lucy Gardner Carson

(AUGUST 3, 2023) At the 2023 International Mesothelioma Interest Group (iMig) conference in June, Brian Cunniff, Ph.D., assistant professor of pathology, presented early experience with “an exciting new therapeutic option for patients suffering with mesothelioma” to a global audience of clinicians, scientists, and allied professionals, according to Business Wire.

Brian Cunniff, Ph.D., assistant professor of pathology and laboratory medicine and chief science officer for RS Oncology

(AUGUST 3, 2023) At the 2023 International Mesothelioma Interest Group (iMig) conference hosted in Lille, France, in June, Brian Cunniff, Ph.D., assistant professor of pathology and laboratory medicine and chief science officer for RS Oncology (RSO), presented early experience with “an exciting new therapeutic option for patients suffering with mesothelioma” to a global audience of clinicians, scientists, and allied professionals, according to Business Wire.

“RSO-021 is an exciting new therapeutic option for patients suffering with mesothelioma,” Cunniff said. “RSO-021 exploits a universal vulnerability of tumor cells through a novel mechanism of action, leaving tumor cells unable to clear toxic waste products. We are excited to see our laboratory findings translated to patients in collaboration with RS Oncology.”

Watch a short clip from the symposium in which Dr. Cunniff explains the discovery of PRX3 and its role in cancer tumors. 

Read full story at Business Wire

Media Relations

To schedule an interview with a faculty member, student, or staff member at the UVM Larner College of Medicine, contact: 

Angela Ferrante, Public Relations Manager
Office
: (802) 656-3111
Mobile: (516) 458-0721